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Edited by Hans-Dieter KlenkAbstract A synthetic peptide corresponding to amino acids (aa)
15–28 of the severe acute respiratory syndrome coronavirus
(SARS-CoV) 3a protein was used to raise polyclonal antibodies
in rabbits. This anti-3a N-terminal antibody could detect 3a pro-
tein in infected cells, as did an anti-3a C-terminal antibody pre-
viously described. The latter targeted the C-terminal cytoplasmic
domain of 3a (aa 134–274). The anti-3a N-terminal antibody
could detect intracellular 3a as well as 3a expressed on the cell
surface. Interestingly, only the anti-3a N-terminal antibody
can inhibit SARS-CoV propagation in Vero E6 culture although
the binding aﬃnity of the anti-3a N-terminal antibody was lower
than the anti-3a C-terminal antibody.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The genome of the severe acute respiratory syndrome coro-
navirus (SARS-CoV) encodes for eight group-speciﬁc proteins
with no signiﬁcance sequence homology to viral proteins of
other coronaviruses [1–3]. The largest of these group-speciﬁc
proteins is termed 3a and the 3a protein has also been shown
to be expressed in SARS-CoV infected cells [4,5] and could
be detected in tissues obtained from SARS patients [5–7]. Anti-
bodies against 3a have also been detected in diﬀerent cohorts
of SARS patients [8–11].
The 3a protein consists of 274 amino acids (aa) and con-
tains three putative transmembrane domains and it is ex-
pressed on the cell surface [4,12]. The topology of 3a on
the cell surface was determined experimentally: its ﬁrst
34 aa, i.e. before the ﬁrst transmembrane domain, is facing
the extracellular matrix and its C-terminal after the third
transmembrane domain (i.e. aa 134–274) is facing the cyto-
plasm [4]. As 3a is a novel coronavirus structural protein
[12,13], its N-terminal ectodomain would be expected to pro-
trude out of the virion. Interestingly, in two separate cohorts*Corresponding authors. Fax: +65 67791117 (Y.-J. Tan);
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doi:10.1016/j.febslet.2006.06.002of SARS patients, one from Taiwan [14] and one from Hong
Kong [15], B cells recognizing the N-terminal region of 3a
were isolated from patients. In addition, it was recently re-
ported that the N terminal of 3a elicits strong and potentially
protective humoral responses in infected patients [11]. In this
study, rabbit polyclonal antibodies targeted against the N-ter-
minal ectodomain and the C-terminal cytoplasmic domain of
the 3a protein were tested for their abilities to inhibit SARS-
CoV propagation in Vero E6 culture.2. Materials and methods
2.1. Cell-line and virus
The Vero E6 cells and SARS-CoV isolate used in this study have
been previously described [16]. Culturing of 293T cells have been pre-
viously described [4].
2.2. Synthesis of peptide and production of rabbit polyclonal antibodies
A peptide ((C)AQPVKIDNASPAST), which corresponds to amino
acids 15–28 of SARS-CoV 3a protein, was synthesized by BioGenes
GmbH (Berlin, Germany). The peptide was conjugated to a carrier,
Limulus Polyphemus Hemocyanine (LPH) from horseshoe crab,
and used to immunize two rabbits using standard protocols. All pro-
cedures were performed by BioGenes GmbH. The immunization
schedule is showed in Table 1. All the sera were tested by Western
blot analysis.
A rabbit polyclonal antibody raised against bacterially-expressed
GST-3a (134-274aa) has been previously described [4]. This antibody
targets the C-terminal cytoplasmic domain of 3a and the 6th bleed
was used in this study. A neutralizing antibody (rabbit anti-SD10) that
targeted the SARS-CoV spike (S) protein was also used in the neutral-
izing assays [17]. The last bleed obtained after 16 immunizations was
used.
2.3. Western blot analysis and immunoﬂuorescence experiments
In order to express recombinant 3a protein in mammalian cells,
Vero E6 cells were transfected with a cDNA construct (pXJ-3a)
for expressing full-length 3a protein, as previously described [4].
Transfected cells were then subjected to Western blot analysis and
immunoﬂuorescence experiments as previously described [4]. Brieﬂy,
cells were grown to 80% conﬂuence in a 6 cm dish and transfected
with 1 lg of the plasmid. The cells were harvested after 16 h and
washed with PBS and then lysed in 1 ml of lysis buﬀer (50 mM Tris,
pH 8, 150 mM NaCl, 0.5% NP40, 0.5% deoxycholic acid, 0.005%
SDS, 1 mM PMSF). After 6 rounds of alternate freezing and
thawing, the cells suspension was centrifuged at 13000 rpm for
20 min at 4 C. The lysates were used for Western blot analysis.
Western blot analysis was also performed on Vero E6 cells infected
with SARS-CoV at a multiplicity of infection (MOI) of 1. At 24 h
post-infection, the cells were washed with PBS and lysed in 350 ll
of lysis buﬀer and the lysate was subjected to Western blot analysis
in a similar manner.blished by Elsevier B.V. All rights reserved.
Table 1
Schedule for the immunization of rabbits (#2 and #3) with a synthetic
peptide corresponding to 15–28 amino acids of SARS-CoV 3a protein
Day Immunization no. Bleed no.
0 1 Pre-immune
7 2 –
14 3 –
28 4 –
35 – 1
49 5 –
63 – 2
77 6 –
91 – 3
120 7 –
127 – 4
141 8 –
148 – 5
3800 S. A˚kerstro¨m et al. / FEBS Letters 580 (2006) 3799–3803For immunoﬂuorescence experiments, the cells were grown on cov-
erslips and transfected as described above. About 16 h later, the cells
were ﬁxed with 4% paraformaldehyde and/or permeabilized with
Triton X-100, and incubated with the relevant antibodies as previously
described [4].
2.4. Enzyme-linked immunosorbent assay (ELISA)
For ELISA, 293T cells were used instead because of their higher
transfection eﬃciency. Cell lysates obtained from untransfected
293T or 293T transiently transfected with pXJ-3a (as described
above) were diluted 1:12 with carbonate buﬀer (pH 9.6) prior to plate
coating. 96-well Nunc Maxisorp microtiter plates (Nalge Nunc Inter-
national, Naperville, IL, USA) were coated with the protein mixtures
at a volume of 50 ll per well by incubation overnight at 4 C. All
subsequent steps were performed at room temperature. The plates
were washed three times with PBS containing 0.05% Tween-20
(PBST) and non-speciﬁc binding sites were blocked with 200 ll per
well of blocking buﬀer (PBST containing 3% BSA) for 1 h. The plates
were further washed another three times before the addition of serum
samples diluted (1:2000 or 1:8000) in blocking buﬀer. Subsequently,
the plates were incubated for 30 min followed by three washes with
PBST. Horse-radish peroxidase (HRP)-conjugated goat anti-rabbit
IgG (Pierce, Rockford, USA; 1:2000 dilution) was added at 50 ll
per well and incubated for 30 min. The plates were then washed three
times in PBST, followed by three times with distilled water and al-
lowed a colour development with the addition of 100 ll per well of
TMB substrate solution (Pierce). After incubation for 15 min in the
dark, the reaction was stopped by adding 100 ll per well of 1 M
H2SO4. The optical densities (OD) were measured at 450 nm. All
experiments were performed in duplicates and the average values with
standard deviations are plotted.
2.5. Neutralization assay
Sera were diluted 1:10 using D-MEM (Gibco) supplemented with 2%
HEPES, 1% antibiotics and 2% inactivated fetal calf serum, and then
inactivated at 56 C for 30 min. The sera were diluted twofold in series
using 100 ll of 2% medium supplemented as described above, in a 96
well plate. To the serum dilutions, virus was added; 25 ll virus stock
(107 PFU ml1) was added to 15 ml of medium and from that a 1/10
dilution was made and 100 ll/well of the last dilution was added to
the serum dilutions. Thus, in all cases, a ﬁxed concentration of the virus
was used except for a virus control, which was diluted 10-folds starting
with the concentration that was added to the serum as described above.
The plates were incubated at 37 C for 60 min, then 100 ll from each
well were transferred to 96 well plates containing Vero E6 cells. At each
dilution, the antiserum and virus mixtures were added to 8 wells. The
96-well plates were incubated in a 37 C CO2 incubator for 48 h, and
the neutralization titers were deduced by the 50% tissue culture infective
dose (TCID50) calculated from the cytopathic eﬀect induced in cell cul-
ture by the virus in the presence of diﬀerent dilutions of antibodies as
previously described [16,18,19]. Brieﬂy, the ratios of infected wells to
uninfected wells were determined by microscopy and the titers of
the neutralizing antibodies were calculated using the Reed–Muench
method [20]. All experiments were performed in duplicates.3. Results and discussion
In this study, we compared the properties of sera obtained a
rabbit that was immunized with bacterially expressed GST-3a
(134–274 aa) (i.e. C-terminal, Rabbit #1, Ref. [4]), and two
rabbits that were immunized with a synthetic peptide corre-
sponding to 15–28 aa of 3a (i.e. N-terminal, Rabbit #2 and
Rabbit #3). This peptide corresponds to aa 15–28 of the
SARS-CoV 3a protein ectodomain which is predicted to face
the extracellular matrix in infected cells [4]. Western blot anal-
ysis was performed to determine the speciﬁcity of the rabbit
polyclonal antibodies. Total cell lysates obtained from Vero
E6 cells transiently transfected with a DNA construct for
expressing full-length 3a or SARS-CoV infected Vero E6 cells
were used in Western blot analysis with sera collected from the
immunized rabbits after diﬀerent number of immunizations
with the peptide. As shown in Fig. 1A, the sera from 1st to
5th bleeds of one of the immunized rabbits (Rabbit #2) could
react speciﬁcally with the full-length 3a protein of 35 kDa.
Similar results were obtained with the other immunized rabbit
(Rabbit #3, Fig. 1B), but the relative reactivity to 3a is lower
than for Rabbit #2. Hence, subsequent experiments were per-
formed with the sera from Rabbit #2.
Western blot analysis of SARS-CoV infected cells also dem-
onstrated that the anti-3a N-terminal antibody (Rabbit #2, 5th
bleed) could react speciﬁcally with the 3a protein expressed in
infected cells (Fig. 1C, lane 2). For comparison, the anti-3a C-
terminal antibody (Rabbit #1, 6th bleed) also detected 3a in in-
fected cells (Fig. 1C, lane 4). Consistent with previous studies
[10,11], the N-terminal of 3a is suﬃcient to stimulate speciﬁcity
antibody response in rabbits. The anti-3a N-terminal antibody
(Rabbit #2, 5th bleed) was used in indirect immunoﬂuores-
cence experiments and it could detect the 3a protein expressed
on the cell surface (Fig. 1D, left panel) and intracellularly
(Fig. 1D, right panel). It was previously showed that properly
folded 3a protein is eﬃciently transported to the cell surface
with its N-terminal facing the extracellular matrix [4,21];
hence, the results showed that the anti-3a N-terminal antibody
could recognize the native form of 3a expressed on the cell
surface.
Next, the rabbit polyclonal antibodies were tested for their
abilities to inhibit SARS-CoV propagation in Vero E6 cul-
ture. Microneutralization assays were performed by mixing
a constant amount of virus with diﬀerent dilutions of rabbit
sera and then overlaying the mixture onto Vero E6 cells in
96-well plates. Calculations were made from the cytopathic
eﬀect induced in cell culture by the virus as described previ-
ously [20]. As shown in Table 2, the sera obtained from the
rabbit immunized with the N-terminal of 3a (Rabbit #2)
showed a neutralization titer of 1:67 for the 1st bleed and
1:80 for the 2nd to 5th bleeds, while the pre-immune serum
did not have any neutralizing activity (titer <1:10). In con-
trast, the anti-3a C-terminal antibody did not show any neu-
tralizing activity (Rabbit #1, 6th bleed, titer <1:10), neither
did the pre-immune serum from this rabbit. All experiments
were performed three times and the average values are
showed in Table 2. The neutralizing activities of the rabbit
sera from Rabbit #2 were observed even though the compo-
nents of the complement system have been inactivated by
heating. In order to determine if this result is reproducible,
the sera from another rabbit immunized with the same 3a
N-terminal peptide (Rabbit #3, Fig. 1B) were used for neu-
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Fig. 1. Detection of SARS-CoV 3a protein expressed in Vero E6 cells with rabbit anti-3a polyclonal antibodies. (A) Rabbit #2 and (B) Rabbit #3:
Western blot analysis was performed using sera obtained from two rabbits that were immunized with a synthetic peptide which corresponds to amino
acids 15–28 of the 3a protein (i.e. N-terminal). All sera were diluted 1:2000 and the lysates were obtained from Vero E6 cells transiently transfected
with a DNA construct for expressing full-length 3a (+) or untransfected cells (). (C) Vero E6 cells were infected with an MOI of 1 and then prepared
for Western blot analysis. Pre-immune serum from the rabbit (Rabbit #2) that was immunized with the 3a N-terminal peptide showed no reactivity
(lane 1), while the 5th bleed from the same rabbit after immunization detected the 3a protein in infected cells (lane 2). Similarly, pre-immune serum
from the rabbit (Rabbit #1) that was immunized with the 3a C-terminal bacterially expressed protein showed no reactivity (lane 3), while the 6th
bleed from the same rabbit after immunization detected the 3a protein in infected cells (lane 4). (D) Cellular localization of 3a in transfected Vero E6
cells as determined by indirect immunoﬂuorescence. Serum from the 5th bleed of the rabbit (Rabbit #2) that was immunized with the 3a N-terminal
peptide was used at a dilution of 1:200 to detect for the 3a protein expressed on the cell surface (left panel, no permeabilization) and intracellularly
(right panel, permeabilization with 0.2% Triton-X 100).
Table 2
Neutralizing titers for the pre-immune sera and the diﬀerent bleeds
obtained from rabbits that have been immunized with either the N- or
C-terminal of the SARS-CoV 3a protein
Bleed no. N-terminal
(Rabbit #2)
C-terminal
(Rabbit #1)
Pre-immune sera <1:10 <1:10
1 1:67a NDb
2 1:80a NDb
3 1:80a NDb
4 1:80a NDb
5 1:80a NDb
6 NDb <1:10
aNeutralizing titers were determined by the Reed–Muench method and
computed as the average of three independent experiments.
bND means not determined.
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Rabbit #3 were also neutralizing, albeit with a lower titer of
1:40 (average value obtained for all the bleeds). For compar-
ison, parallel experiments were also performed with a neutral-
izing antibody targeting 1055–1192 aa (SD10), which contains
the heptad repeat 2 domain known to be important for medi-
ating membrane fusion, of SARS-CoV S protein [17]. In thisexperiment, the rabbit anti-SD10 polyclonal antibody had a
neutralizing titer of 1:160, which is consistent with our previ-
ous ﬁndings [17].
To be certain that the inability of the anti-3a C-terminal
antibody to neutralize the SARS-CoV is not due to lower anti-
body concentrations, we determined the relative binding aﬃn-
ities of the anti-3a N-terminal and C-terminal rabbit
polyclonal antibodies to 3a protein expressed in 293T cells
by ELISA. Diluted rabbit sera were added to wells coated with
total cell lysates from untransfected cells or cells transiently
transfected with a DNA construct for expressing the full-
length 3a protein. The OD diﬀerence (in arbitrary units) repre-
sented the speciﬁc binding of antibody to the 3a protein. As
shown in Fig. 2, the serum from Rabbit #1 (i.e. C-terminal,
6th bleed) has relatively stronger binding aﬃnity to the 3a pro-
tein than the sera from diﬀerent bleeds of Rabbit #2 (i.e. N-ter-
minal). The pre-immune sera from both rabbits showed little
binding to 3a. Hence, it is clear that the anti-3a C-terminal
antibody did not have any neutralizing activity, even though
it contains a relatively higher level of 3a-speciﬁc antibodies
than the anti-3a N-terminal antibody.
Interestingly, B cells recognizing the N-terminal ectodo-
main of the 3a protein were found in two separate cohorts
1: 2000 dilution
1: 8000 dilution
r
effid
 
D
O
en
ce
r
effid
 
D
O
en
ce
0
0.2
0.4
0.6
0.8
1A
B
Rabbit#1
pre-
immune
Rabbit#1
6th bleed
Rabbit#2
pre-
immune
Rabbit#2
1st bleed
Rabbit#2
2nd bleed
Rabbit#2
3rd bleed
Rabbit#2
4th bleed
Rabbit#2
5th bleed
0
0.2
0.4
0.6
0.8
1
Rabbit#1
pre-
immune
Rabbit#1
6th bleed
Rabbit#2
pre-
immune
Rabbit#2
1st bleed
Rabbit#2
2nd bleed
Rabbit#2
3rd bleed
Rabbit#2
4th bleed
Rabbit#2
5th bleed
serum type
serum type
Fig. 2. Binding aﬃnity of rabbit polyclonal antibodies to 3a protein expressed in 293T cells as determined by ELISA. Rabbit sera were diluted 1:2000
(A) or 1:8000 (B) and added to wells coated with total cell lysates from untransfected cells or cells transiently transfected with a DNA construct for
expressing the full-length 3a protein. The OD diﬀerence (in arbitrary units) represented the speciﬁc binding of antibody to the 3a protein. Rabbit #1
was immunized with bacterially expressed GST-3a (134–274 aa) (i.e. C-terminal) and the pre-immune serum and the serum from the 6th bleed were
tested. Rabbit #2 was immunized with a synthetic peptide corresponding to amino acids 15–28 of 3a (i.e. N-terminal). For Rabbit #2, the pre-
immune serum and the sera from the 1st to 5th bleeds were tested. All experiments were performed in duplicates and the average values with standard
deviations are plotted.
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48.8% of patients who recovered from SARS had antibodies
against the N terminal of 3a while only 7.4% of the diseased
patients has such antibodies [11]. It was further demonstrated
that anti-3a antibodies in the patient serum could bind cells
expressing 3a and induce the elimination of these cells in
the presence of the human complement system [11]. Several
other studies also found that anti-3a antibodies were pre-
sented only in a subset of SARS patients [4,9,10,22]. In this
study, we showed that rabbit polyclonal antibody targeting
a 14 aa epitope (aa 15–28) in the N-terminal ectodomain of
3a could neutralize the SARS-CoV replication in Vero E6
cells in the absence of the complement system. On the other
hand, serum obtained from a rabbit immunized with the C-
terminal cytoplasmic domain of 3a (aa 134–274) was not
capable of neutralizing SARS-CoV even though it contains
a higher amount of 3a-speciﬁc antibodies. Hence, it is clear
that both the ectodomain and cytoplasmic domain of 3aare immunogenic but only the ectodomain stimulates neutral-
izing antibodies.
To our knowledge, this is the ﬁrst report of a SARS-CoV
group-speciﬁc protein that can induce neutralizing antibody.
Our results showed that antibody targeting the N-terminal of
3a can inhibit SARS-CoV replication, suggesting that 3a can
stimulate protective humoral responses during SARS infec-
tion. This ﬁnding is consistent with a recent report that a higher
percentage of patients who recovered from SARS infection
have antibodies against the N-terminal of 3a, when compared
to the patients who died from SARS infection [11]. Even
though the 3a protein is not essential for SARS-CoV replica-
tion in cell culture and the murine model [23], it is very likely
that 3a contributes to viral replication or pathogenesis in the
natural host(s). In future studies, it will be crucial to determine
the role of 3a during SARS-CoV infection in non-human pri-
mate models, where the animals could develop a disease com-
parable to that in SARS patients [24]. The precise role of aa
S. A˚kerstro¨m et al. / FEBS Letters 580 (2006) 3799–3803 380315–28 in the N-terminal ectodomain of the 3a protein during
SARS-CoV infection also remains to be elucidated.References
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